PRKCB

Across TCGA pan-cancer cohorts, PRKCB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKCB data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PRKCB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKCB expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where PRKCB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.884	1.000	.018	42	view →
LUAD	DFS	Tertile	All	0.859	0.408	<.001	13	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	12	view →
HNSC	DFS	Quartile	All	0.879	1.000	.006	10	view →
CCRCC	OS	Quartile	All	0.771	0.996	.017	6	view →
LSCC	OS	Tertile	III,IV	0.970	0.553	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKCB–COAD (DFS)

Open the COAD breakdown →